The Food and Drug Administration (FDA) has approved Auvelity ® (dextromethorphan HBr and bupropion HCl) for the treatment of agitation associated with dementia due to Alzheimer d ...

The Food and Drug Administration (FDA) has placed a hold on the enrollment of new patients in the phase 3 ENIGMA-TRS 2 study evaluating evenamide in treatment-resistant schizophrenia.

Novo Nordisk submitted a BLA to the Food and Drug Administration for denecimig for the treatment of hemophilia A in September 2025.

About one-third of children and adolescents use dietary supplements in the US, according to a study published online April 24 in Pediatrics Open Science. Brandy ...

MPR spoke with Dr Daniela Carvalho, an investigator in the CHORD trial, the results form which formed the basis for the approval of Otarmeni.

Data from ARTISTRY trials demonstrated that switching to a single-tablet regimen of bictegravir and lenacapavir is ...

Rectal cancer is occurring earlier and killing younger adults faster, according to a study presented at Digestive Disease Week 2026, held from May 2 to 5 in Chi ...

Difference in total body weight loss between the treatment and control groups widened with time postintervention.

A reduction in the risk for diabetes with vitamin D3 was seen among 1480 participants with Apal AC and CC genotypes. HealthDay News — For adults with prediabetes, a reduction in the risk for diabetes ...

Topline data from the MagnetisMM-5 study demonstrate the superiority of elranatamab monotherapy over daratumumab plus pomalidomide and dexamethasone in double-class exposed multiple myeloma patients.

Under the Bridge program, eligible beneficiaries can get Medicare coverage of GLP-1s for obesity for a $50 copay. Extending the short-term GLP-1 Bridge program is good news for eligible Medicare ...

Phase 3 trial results demonstrate that bepirovirsen significantly increases the proportion of patients achieving functional cure compared with placebo.